In a variety of cancers, including ovarian cancer, MAGEA proteins (part of a large family of melanoma antigen genes, (MAGEs)—also a subgroup of CTA antigens) are found more frequently and with higher expression levels than NY-ESO-1 and are therefore thought to represent more promising and potent targets for immunotherapy [138]. This evidence concerns the gene CTAG1B and ovarian cancer.